[go: up one dir, main page]

WO1996019991A1 - Benzimidazoles as inhibitors of calcitriol metabolism - Google Patents

Benzimidazoles as inhibitors of calcitriol metabolism Download PDF

Info

Publication number
WO1996019991A1
WO1996019991A1 PCT/EP1995/005172 EP9505172W WO9619991A1 WO 1996019991 A1 WO1996019991 A1 WO 1996019991A1 EP 9505172 W EP9505172 W EP 9505172W WO 9619991 A1 WO9619991 A1 WO 9619991A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
alkyl
phenyl
calcitriol
cycloalkyl
Prior art date
Application number
PCT/EP1995/005172
Other languages
French (fr)
Inventor
Hugo Florent Adolf Vanden Bossche
Gustaaf Henri Maria Willemsens
Roland De Coster
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Priority to AU44361/96A priority Critical patent/AU4436196A/en
Priority to EP95943236A priority patent/EP0800391A1/en
Priority to JP8520221A priority patent/JPH10511653A/en
Publication of WO1996019991A1 publication Critical patent/WO1996019991A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention is concerned with the use of (1H-imidazol-1-yl)methyl-1H-benzimidazoles for the manufacture of a medicament for treating a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol.
  • Calcitriol (generic to l ⁇ ,25-dihydroxy-vitamin D 3 ) is endogenously formed from vitamin D 3 by metabolic reactions and appears to carry out all the functions attributed to the vitamin D hormone system.
  • Vitamin D compounds are involved in the regulation of calcium and phosphate homeostasis and bone mineralisation.
  • the daily requirements of vitamin D are met by exposure to sunlight and/or obtained from the diet. In case of inadequate exposure to sunlight and/or a lack of the vitamin in the diet, problems of vitamin D deficiency may arise. These problems are further aggravated by the rapid metabolism of calcitriol to inactive compounds.
  • calcitriol has been described to show antiinflammatory and immunomodularing activity. It has also been shown that calcitriol stimulates the differentiation of cells and has inhibitory activity on cell proliferation. Moreover, the compound has potential use in the treatment of hypertension and diabetes mellitus. The therapeutic potential of exogenously administered calcitriol, however, is limited by its rapid metabolic degradation. Furthermore, excessive intake of the compound leads to the development of adverse effects. (1H-imidazol-1-yl)methyl-1H-benzimidazoles have been described in EP-0,260,744 having inhibitory activity on androgen formation and are useful in preventing or therapeutically treating androgenic hormone dependent disorders. EP-0,371,559 discloses the use of these compounds to suppress the metabolism of retinoids.
  • Said property can be used to control the rate of growth and differentiation of normal, preneoplastic and neoplastic epithelial cells, thus making these compounds useful in the treatment of carcinoma and keratinization disorders.
  • the (+) isomer of 5-[3-chlorophenyl]-1H-imidazol-1-ylmethyl]-1H-benzimidazole has been described in WO 95/22540, published on August 24, 1995, as being particularly useful in the field of dermatology.
  • the (-) isomer of 5-[3-chlorophenyl]-1H-imidazol-1-ylmethyl]-1H-benzimidazole has been described in WO 95/22541, published on August 24, 1995, as being particularly useful in the field of oncology.
  • the (1H-imidazol-1-yl)methyl-1H-benzimidazoles described in the present invention inhibit the metabolic degradation of calcitriol and overcome certain problems associated with art known vitamin D therapy.
  • the present invention relates to the use of (1H-imidazol-1-yl)methyl-1H-benzimidazoles, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, for the manufacture of a medicament for treating a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol, said benzimidazoles having the formula
  • R is hydrogen; C 1- 10 alkyl; C 3-7 cycloalkyl; Ar 1 or Ar 1 -C 1-6 alkyl;
  • R 1 is hydrogen; C 3-7 cycloalkyl; Ar 1 ; C 1-10 alkyl; C 1 -6 alkyl substituted with Ar 1 or C 3-7 cycloalkyl; hydroxy; C 1- 10 alkyloxy; C 1-6 alkyloxy substituted with Ar 1 or
  • R 2 is hydrogen; halo; C 1- 10 alkyl; C 1-4 alkyl substituted with up to 4 halo atoms;
  • each Ar 1 independently is phenyl, substituted phenyl, pyridinyl, aminopyridinyl, imidazolyl, thienyl, halothienyl, furanyl, halofuranyl or thiazolyl;
  • each Ar 2 independently is phenyl or substituted phenyl
  • said substituted phenyl represents phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, trifluoromethyl,
  • halo is generic to fluoro, chloro, bromo and iodo;
  • C 1 -4 alkyl is meant to include straight and branch chained saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl.
  • C 1-6 alkyl includes C 1-4 alkyl radicals and the higher homologs thereof having 5 or 6 carbon atoms
  • C 1-10 alkyl is meant to include C 1-6 alkyl radicals, as defined hereinabove, and the higher homologs thereof having from 7 to 10 carbon atoms
  • C 3-7 cycloalkyl is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl
  • C 3-6 alkenyl defines straight chained and branched hydrocarbon radicals containing one double bond having from 3 to 6 carbon atoms such as, for example, 3-propenyl, 2-butenyl and the like
  • C 3-6 alkynyl defines straight chained and branched hydrocarbon radicals containing one triple bond and having from 3
  • addition salts as mentioned herein are meant to comprise the therapeutically active addition salt forms which the compounds of formula (I) are able to form with appropriate acids, such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
  • inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid
  • sulfuric nitric; phosphoric and the like acids
  • the pharmaceutically acceptable addition salts as mentioned hereinabove are also meant to comprise the therapeutically active non-toxic base, in particular, a metal or amine addition salt forms which the compounds of formula (I) are able to form.
  • Said salts can conveniently be obtained by treating the compounds of formula (I) containing acidic hydrogen atoms with appropriate organic and inorganic bases such as, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
  • organic bases e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like
  • salt forms can be converted by treatment with an appropriate base or acid into the free acid or base form.
  • addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) are able to form and said solvates are meant to be included within the scope of the present invention. Examples of such solvates are, e.g. the hydrates, alcoholates and the like.
  • the compounds of formula (I) wherein R is other than hydrogen have an asymmetric carbon atom in their structure, the absolute configuration of which may be represented by the descriptors R and S.
  • Formula (I) is intended to encompass all enantiomers and diastereoisomers of the compounds of the invention as well as the mixtures thereof, in particular the racemates and the enantiomerically pure forms (i.e. the enantiomeric excess is equal to or higher than 95%).
  • the compounds of formula (I) may contain in their structure a tautomeric system and, consequently, these compounds can be represented by each of their tautomeric forms. All tautomeric forms are meant to be embraced by the definition of the compounds of formula (I).
  • the present invention is concerned with the use of a compound of formula (I) wherein R is phenyl or substituted phenyl; R 1 is hydrogen or C 1-6 alkyl; R 2 is hydrogen; halo; C 1-6 alkyl; C 1-4 alkyl substituted with up to 4 halo atoms;
  • More interesting compounds are the compounds of formula (I) wherein the 1H-imidazol-1-ylmethyl moiety is substituted on either the 5 or 6 position of the benzimidazole ring.
  • R 1 is hydrogen
  • R 2 is hydrogen, C 1-6 alkyl or phenyl
  • the preferred compounds within the invention are ( ⁇ )-5-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-benzimidazole (generically known as liarozole), (+)-liarozole, (-) liarozole and the pharmaceutically acceptable addition salts thereof, in particular, the hydrochloride and the fumarate salts such as, for example, liarozole hydrochloride, liarozole fumarate, (+)-liarozole hydrochloride and (-)-liarozole hydrochloride.
  • Vitamin D 3 is sequentially metabolized by enzymes, first to 25-hydroxy-vitamin D 3 in the liver and then to either 24,25-dihydroxy-vitamin D 3 or the active hormonal form 1 ⁇ ,25-dihydroxy-vitamin D 3 in the kidney.
  • Vitamin D 3 (generically known as cholecalciferol) and 25-hydroxy-vitamin D 3 (generically known as calcifediol), therefore, are prodrugs of the subject active compound calcitriol.
  • Another prodrug of calcitriol is 1 ⁇ -hydroxy-vitamin D 3 (generically known as alfacalcidol), which is hydroxylated at the 25 position in the liver to give calcitriol.
  • Calcitriol is further metabolized to inactive degradation products, e.g. in the kidney and the skin.
  • the compounds of formula (I) are useful in inhibiting the metabolic degradation of endogenously formed and exogenously administered calcitriol.
  • the inhibitory activity of the compounds of formula (I) on the metabolic degradation of calcitriol is evidenced by measuring the impact of said compounds on the calcitriol degradation in human foreskin keratinocytes, pig kidney cells and human hepatoma cells, as described hereinafter.
  • the therapeutic potential of the compounds of formula (I), optionally in combination with calcitriol or a prodrug thereof, preferably, cholecalciferol, calcifediol or alfacalcidol extends to all pathological conditions which are beneficially influenced by inhibiting the metabolic degradation of calcitriol.
  • the compounds of formula (I) optionally in combination with calcitriol or a prodrug thereof, preferably, cholecalciferol, calcifediol or alfacalcidol can be useful in the treatment of vitamin D deficiency states.
  • Vitamin D deficiency may arise from inadequate exposure to sunlight and/or from a lack of the vitamin in the diet and is further aggravated by the rapid metabolic degradation of calcitriol, and leads to a syndrome characterized by hypocalcaemia, hypophosphataemia, bone softening and bone pain.
  • Other clinical applications of the compounds of formula (I) optionally in combination with calcitriol or a prodrug thereof, preferably, cholecalciferol, calcifediol or alfacalcidol, are reviewed by Bouillon et al., Endocrine Reviews (1995) 16(2), 200-257 and include metabolic bone disorders, e.g.
  • osteoporosis osteopetrosis and the like; primary and depoty hyperparathyroidism; renal osteodystrophy; diseases of the immune system or other conditions characterized by an abnormal interleukin production, e.g. inflammatory diseases such as rheumatoid arthritis and asthma; hypertension; diabetes mellitus;
  • cancer e.g. leukemia, carcinoma, sarcoma, lymphoma and the like
  • keratinization disorders e.g. acne, psoriasis, lamellar ichthyosis, plantar warts, callosities, acanthosis nigricans, lichen planus, molluscum, melasma, corneal epithelial abrasion, geographic tongue, Fox-Fordyce disease, cutaneous metastatic melanoma and keloids, epidermolytic hyperkeratosis, Darier's disease, pityriasis rubra pilaris, congenital ichthyosiform erythroderma, hyperkeratosis palmaris et plantaris, and similar disorders.
  • cancer e.g. leukemia, carcinoma, sarcoma, lymphoma and the like
  • keratinization disorders e.g. acne, psoriasis
  • the present invention concerns the use of (1H-imidazol-1-yl)methyl-1H-benzimidazoles of formula (I) for the manufacture of a medicament for treating a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol. Also, the present invention concerns a method of treating patients suffering from a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol, said method consisting of administering to a patient an effective amount of a compound of formula (I), an addition salt or a stereochemically isomeric form thereof.
  • Another aspect of the incvention concerns the use of (1H-imidazol-1-yl)methyl-1H-benzimidazoles of formula (I) in combination with calcitriol or a prodrug thereof for the manufacture of a medicament for treating a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol.
  • this aspect of the invention concerns a method of treating patients suffering from a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol, in particular keratinization disorders such as psoriasis, said method consisting of administering to a patient (a) an effective amount of calcitriol or a prodrug thereof and (b) an effective amount of a compound of formula (I), an addition salt or a stereochemically isomeric form thereof.
  • the invention relates to a single drug therapy involving a compound of formula (I), as well as a combination therapy including a compound of formula (I) and calcitriol or a prodrug thereof.
  • the active ingredients each independently may be administered orally, rectally, percutaneously, topically or by parenteral injection, depending on the affliction to be treated and the evaluation of the physician prescribing the treatment with the subject drugs.
  • the drugs each independently are administered orally or topically.
  • the compounds of formula (I) and calcitriol or a prodrug thereof may be administered separately (i.e. simultaneously, concurrently or consecutively) or the different drugs may be combined in one dosage form.
  • a particular embodiment of the invention relates to a product containing (a) a
  • the product contains (a) a pharmaceutical composition containing an effective amount of calcitriol or a prodrug thereof and (b) a pharmaceutical composition containing an effective amount of ( ⁇ )-5-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-benzimidazole (generically known as liarozole), (+)-liarozole, (-) liarozole or a pharmaceutically acceptable addition salt thereof, in particular, liarozole hydrochloride, liarozole fumarate, (-f-)-liarozole hydrochloride and (-)-liarozole hydrochloride.
  • Such products may comprise, for example, a kit comprising a container with a suitable composition containing calcitriol or a prodrug thereof and another container comprising a compound of formula (I), an addition salt or a stereochemically isomeric form thereof.
  • Such a product may have the advantage that a physician can select on the basis of the diagnosis the appropriate amounts of each component and the sequence and timing of the administration thereof.
  • the drugs are preferably formulated in specific compositions thereof.
  • compositions there may be cited all compositions usually employed for systemically or topically administering drugs.
  • compositions of this invention an effective amount of the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • a pharmaceutically acceptable carrier which carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral hquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets.
  • tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed.
  • the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included.
  • injectable solutions for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution.
  • injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed.
  • the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
  • a penetration enhancing agent and/or a suitable wetting agent optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin.
  • suitable additives e.g. creams, gels, dressings, shampoos, tinctures, pastes, ointments, salves, powders and the like.
  • compositions may be by aerosol, e.g. with a propellent such as nitrogen carbon dioxide, a freon, or without a propellent such as a pump spray, drops, lotions, or a semisolid such as a thickened composition which can be applied by a swab.
  • a propellent such as nitrogen carbon dioxide, a freon
  • a propellent such as a pump spray
  • drops lotions
  • a semisolid such as a thickened composition which can be applied by a swab.
  • ⁇ -, ⁇ - or ⁇ -cyclodextrins or their derivatives in particular hydroxyalkyl substituted cyclodextrins, e.g.
  • Dosage unit form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets
  • compositions are preparations of the cosmetic type, such as toilet waters, lotions, skin milks or milky lotions.
  • Said preparations contain, besides the active ingredients, components usually employed in such preparations.
  • components usually employed in such preparations.
  • examples of such components are oils, fats, waxes, surfactants, humectants, thickening agents, antioxidants, viscosity stabilizers, chelating agents, buffers, preservatives, perfumes, dvestuffs, lower alkanols, and the like.
  • covers may be used, e.g. plasters, bandages, dressings, gauze pads and the like, containing an appropriate amount of a composition as referred hereinabove.
  • covers may be applied which have been impregnated or sprinkled with a liquid formulation containing the active agents, or strewn with a powdery solid composition, or smeared, covered or coated with a semiliquid composition.
  • compositions are those adapted for topical administration.
  • the latter compositions comprise a skin-acceptable carrier, an effective amount of a compound of formula (I), an addition salt or a stereochemically isomeric form thereof, and an effective amount of calcitriol or a prodrug thereof.
  • an effective daily dose of a compound of formula (I), an addition salt or a stereochemically isomeric form thereof would be from 0.001 mg/kg to 20 mg/kg body weight and more preferably from 0.01 mg/kg to 10 mg/kg body weight.
  • the effective daily dose of calcitriol or a prodrug thereof ranges from about 0.1 ⁇ g to about 10 mg, in particular from about 0.5 ⁇ g to about 1 mg and preferably from about 1 ⁇ g to about 0.1 mg. It may be appropriate to administer the required dose as several sub-doses at appropriate intervals throughout the day.
  • (+)-liarozole hydrochloride, (-)-liarozole hydrochloride or ( ⁇ )-liarozole hydrochloride is suitably administered b.i.d..
  • compositions for topical application comprise from 0.005 to 0.5% w/w (particularly from 0.01 to 0.1%) calcitriol and/or from 0.05 to 5% of (+)-liarozole hydrochloride, (-)-liarozole hydrochloride or ( ⁇ )-liarozole hydrochloride, in a semi-solid or liquid diluent or carrier.
  • the topical compositions are applied to the area to be treated or protected at regular intervals as needed, generally about 7 to about 21 times per week. The duration of the treatment will depend upon the nature and severity of the condition to be treated as well as the frequency of application of the composition.
  • Active ingredient 1 (A.I. 1) as used throughout these examples relates to a compound of formula (I), a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.
  • Active ingredient 2 (A.I. 2) relates to calcitriol or a prodrug thereof. Formulations containing a single active ingredient as well as those comprising both active ingredients are exemplified.
  • 75 mg stearyl alcohol, 2 mg cetyl alcohol, 20 mg sorbitan monostearate and 10 mg isopropyl myristate are introduced into a doublewall jacketed vessel and heated until the mixture has completely molten.
  • This mixture is added to a separately prepared mixture of purified water, 200 mg propylene glycol and 15 mg polysorbate 60 having a temperature of 70 to 75°C while using a homogenizer for liquids.
  • the resulting emulsion is allowed to cool to below 25°C while continuously mixing.
  • a mixture of 2 g A.I. 1 and/or 0.02 g A.I. 2 microfine, 20 g phosphatidyl choline, 5 g cholesterol and 10 g ethyl alcohol is stirred and heated at 55-60°C until complete dissolution and is added to a solution of 0.2 g methyl paraben, 0.02 g propyl paraben,
  • a mixture of 10 g phosphatidyl choline and 1 g cholesterol in 7.5 g ethyl alcohol is stirred and heated at 40°C until complete dissolution.
  • 2 g A.I. 1 and/or 0.02 g A.I. 2 microfine is dissolved in purified water by mixing while heating at 40°C.
  • the alcoholic solution is added slowly to the aqueous solution while homogenizing during 10 minutes.
  • Example 10 Metabolism of calcitriol by human foreskin keratinocytes, pig kidney cells and human hepatoma cells
  • the dermal and epidermal tissues of human foreskin was cut in 0.5 cm ⁇ pieces and incubated overnight at 4°C in 10 ml phosphate buffer (PBS) without calcium and magnesium, containing 2 ml Dispase II (a protease supplied by Boehringer Mannheim at an activity of 24U/ml). After incubation, the tissue was placed in 15 ml trypsin
  • the epidermal fraction was carefully lifted with a pincet. By gently scraping the dermis, the adherent keratinocytes were released from the tissue into the trypsin solution. After removal of all dermal parts, the remaining solution (containing the keratinocytes and the stratum corneum sheets) was incubated for 20 min. at 37°C. After filtration, the filter was washed once with keratinocyte-free medium (SFM) and fetal calf serum was added to the filtrate to reach a final concentration of 10% (inactivation of the trypsin-EDTA). After centrifugation of the cell suspension (10 min.
  • SFM keratinocyte-free medium
  • the cells were counted and plated in keratinocyte-SFM (supplemented with an antibiotic-antimycotic mix and 2 ⁇ g gentamycin/ml) at a cell density of 3.10 6 cells/75 cm 2 tissue culture flask and incubated at 37°C in a 5%-CO 2 humidified atmosphere. After 2-3 days of cultivation, the medium was replaced by antibiotic-antimycotic-free medium. After reaching confluence, cells were trypsinized and, after inactivation of the remaining trypsine by fetal calf serum, seeded in 6-well-plates at a cell density of 1.10 5 cells/ml keratinocyte-SFM.
  • the medium was refreshed every 2-3 days and 16 hours before the onset of the experiment.
  • the medium was again replaced by 2 ml of keratinocyte-SFM.
  • the calcitriol metabolism was initiated by adding 0.1 ⁇ Ci 1 ⁇ ,25-[26,27-3H]-dihydroxyvitamin-D 3 in 10 ⁇ l ethanol and 2 ⁇ l drug and/or solvent (DMSO).
  • DMSO drug and/or solvent
  • the medium was transferred into a brown coloured test tube containing 3 ml chloroform and 0.5 ml 10% formic acid.
  • the cells were trypsinized with 0.5 ml trypsine (0.125%) - EDTA (0.01%) and after 15 min.
  • Pig kidney cells collected from one 75 cm 2 tissue culture flask were suspended in 160 ml Medium 199 (a synthetic culture medium supplied by Life-Technologies) containing 3% foetal calf serum (FCS). Two ml of the cell suspension were seeded in 6-well plates and incubated at 37°C in a humidified 5% CO2 atmosphere. The medium was refreshed every 2-3 days. At the onset of the experiment, confluent cultures were washed with phosphate buffer (PBS) without calcium and magnesium and refreshed with with 2 ml medium 199 without serum. The metabolism of l ⁇ ,25-[26,27- 3 H]-dihydroxyvitamin- D 3 was studied as described for the human foreskin keratinocytes.
  • PBS phosphate buffer
  • Human hepatoma cells were grown at 37°C (in a CO 2 incubator) in 2 ml REG A-3 medium (a synthetic culture medium supplied by Life-Technologies) supplemented with 5% FCS. After 24 h of growth, 1.25 ⁇ Ci [ 14 C]-acetate, drug and/or DMSO were added and cells were grown for another 24 h. At the end of the incubation period, cells were collected by centrifugation, washed with physiological saline and resuspended in 1 ml H 2 O and 1 ml 15% KOH in 90% ethanol. The metabolism of 1 ⁇ ,25-[26,27- 3 H]- dihydroxyvitamin-D 3 was studied as described for the human foreskin keratinocytes.
  • IC 50 values for the compounds of formula (I) were calculated by conventional techniques. Table 1 summarizes the obtained IC 50 values for some of the subject compounds.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The invention relates to the use of a (1H-imidazol-1-yl)methyl-1H-benzimidazole, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, for the manufacture of a medicament for treating a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol, said benzimidazole having formula (I), wherein R is hydrogen; C1-10alkyl; C3-7cycloalkyl; Ar?1 or Ar1-C¿1-6alkyl; R1 is hydrogen; C¿3-7?cycloalkyl; Ar?1¿; C¿1-10?alkyl; C1-6alkyl substituted with Ar?1¿ or C¿3-7?cycloalkyl; hydroxy; C1-10alkyloxy; C1-6alkyloxy substituted with Ar?1¿ or C¿3-7?cycloalkyl; C3-6alkenyloxy optionally substituted with Ar?2; C¿3-6alkynyloxy optionally substituted with Ar?2; or Ar1-oxy; R2¿ is hydrogen; halo; C¿1-10?alkyl; C1-4alkyl substituted with up to 4 halo atoms; C3-7cycloalkyl; Ar?1¿; quinolinyl; indolinyl; C¿1-6?alkyl substituted with Ar?1, C¿3-7cycloalkyl, quinolinyl, indolinyl or hydroxy; C1-10alkyloxy; C1-6alkyloxy substituted with Ar1 or C¿3-7?cycloalkyl; C3-6alkenyl optionally substituted with Ar?1; Ar2¿-oxy; C¿1-6?alkyloxycarbonyl; carboxyl; C1-6alkylcarbonyl; Ar?1¿-carbonyl or Ar1-(CHOH)-; compositions comprising calcitriol or a prodrug thereof and a compound of formula (I).

Description

BENZIMIDAZOLES AS INHIBITORS OF CALCITRIOL METABOLISM
The present invention is concerned with the use of (1H-imidazol-1-yl)methyl-1H-benzimidazoles for the manufacture of a medicament for treating a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol.
Calcitriol (generic to lα,25-dihydroxy-vitamin D3) is endogenously formed from vitamin D3 by metabolic reactions and appears to carry out all the functions attributed to the vitamin D hormone system. Vitamin D compounds are involved in the regulation of calcium and phosphate homeostasis and bone mineralisation. The daily requirements of vitamin D are met by exposure to sunlight and/or obtained from the diet. In case of inadequate exposure to sunlight and/or a lack of the vitamin in the diet, problems of vitamin D deficiency may arise. These problems are further aggravated by the rapid metabolism of calcitriol to inactive compounds.
Further, calcitriol has been described to show antiinflammatory and immunomodularing activity. It has also been shown that calcitriol stimulates the differentiation of cells and has inhibitory activity on cell proliferation. Moreover, the compound has potential use in the treatment of hypertension and diabetes mellitus. The therapeutic potential of exogenously administered calcitriol, however, is limited by its rapid metabolic degradation. Furthermore, excessive intake of the compound leads to the development of adverse effects. (1H-imidazol-1-yl)methyl-1H-benzimidazoles have been described in EP-0,260,744 having inhibitory activity on androgen formation and are useful in preventing or therapeutically treating androgenic hormone dependent disorders. EP-0,371,559 discloses the use of these compounds to suppress the metabolism of retinoids. Said property can be used to control the rate of growth and differentiation of normal, preneoplastic and neoplastic epithelial cells, thus making these compounds useful in the treatment of carcinoma and keratinization disorders. The (+) isomer of 5-[3-chlorophenyl]-1H-imidazol-1-ylmethyl]-1H-benzimidazole has been described in WO 95/22540, published on August 24, 1995, as being particularly useful in the field of dermatology. The (-) isomer of 5-[3-chlorophenyl]-1H-imidazol-1-ylmethyl]-1H-benzimidazole has been described in WO 95/22541, published on August 24, 1995, as being particularly useful in the field of oncology. Quite unexpectedly, the (1H-imidazol-1-yl)methyl-1H-benzimidazoles described in the present invention inhibit the metabolic degradation of calcitriol and overcome certain problems associated with art known vitamin D therapy.
The present invention relates to the use of (1H-imidazol-1-yl)methyl-1H-benzimidazoles, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, for the manufacture of a medicament for treating a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol, said benzimidazoles having the formula
Figure imgf000004_0001
wherein
R is hydrogen; C1- 10alkyl; C3-7cycloalkyl; Ar1 or Ar1-C1-6alkyl;
R1 is hydrogen; C3-7cycloalkyl; Ar1; C1-10alkyl; C1 -6alkyl substituted with Ar1 or C3-7cycloalkyl; hydroxy; C1- 10alkyloxy; C1-6alkyloxy substituted with Ar1 or
C3-7cycloalkyl; C3-6alkenyloxy optionally substituted with Ar2; C3-6alkynyloxy optionally substituted with Ar2; or Ar1-oxy;
R2 is hydrogen; halo; C1- 10alkyl; C1-4alkyl substituted with up to 4 halo atoms;
C3-7cycloalkyl; Ar1; quinolinyl; indolinyl; C1 -6alkyl substituted with Ar1,
C3-7cycloalkyl, quinolinyl, indolinyl or hydroxy; C1-10alkyloxy; C1-6alkyloxy substituted with Ar1 or C3-7cycloalkyl; C3-6alkenyl optionally substituted with Ar1; Ar2-oxy; C1-6alkyloxycarbonyl; carboxyl; C1-6alkylcarbonyl; Ar1-carbonyl or
Ar1-(CΗOΗ)-;
each Ar1 independently is phenyl, substituted phenyl, pyridinyl, aminopyridinyl, imidazolyl, thienyl, halothienyl, furanyl, halofuranyl or thiazolyl;
each Ar2 independently is phenyl or substituted phenyl;
in Ar1 and Ar2 said substituted phenyl represents phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, trifluoromethyl,
C1-6alkyl, C1-6alkyloxy, cyano, amino, mono- and di(C1 -6alkyl)amino, nitro, carboxyl, formyl and C1 -6alkyloxycarbonyl.
As used in the foregoing definitions the term halo is generic to fluoro, chloro, bromo and iodo; the term "C1 -4alkyl" is meant to include straight and branch chained saturated hydrocarbon radicals having from 1 to 4 carbon atoms such as, for example, methyl, ethyl. 1-methylethyl, 1,1-dimethylethyl, propyl, 2-methylpropyl, butyl and the like; "C1-6alkyl" includes C1-4alkyl radicals and the higher homologs thereof having 5 or 6 carbon atoms; " C1-10alkyl" is meant to include C1-6alkyl radicals, as defined hereinabove, and the higher homologs thereof having from 7 to 10 carbon atoms; the term "C3-7cycloalkyl" is generic to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl; "C3-6alkenyl" defines straight chained and branched hydrocarbon radicals containing one double bond having from 3 to 6 carbon atoms such as, for example, 3-propenyl, 2-butenyl and the like; "C3-6alkynyl" defines straight chained and branched hydrocarbon radicals containing one triple bond and having from 3 to 6 carbon atoms such as, for example, 3-propynyl, 2-butynyl and the like; and when a C3-6alkenyl or a C3-6alkynyl is substituted on a heteroatom, then the carbon atom of said C3-6alkenyl or said C3-6alkynyl connected to said heteroatom preferably is saturated.
The addition salts as mentioned herein are meant to comprise the therapeutically active addition salt forms which the compounds of formula (I) are able to form with appropriate acids, such as, for example, inorganic acids such as hydrohalic acids, e.g. hydrochloric or hydrobromic acid; sulfuric; nitric; phosphoric and the like acids; or organic acids such as, for example, acetic, propanoic, hydroxyacetic, lactic, pyruvic, oxalic, malonic, succinic, maleic, fumaric, malic, tartaric, citric, methanesulfonic, ethanesulfonic, benzenesulfonic, p-toluenesulfonic, cyclamic, salicylic, p-aminosalicylic, pamoic and the like acids.
The pharmaceutically acceptable addition salts as mentioned hereinabove are also meant to comprise the therapeutically active non-toxic base, in particular, a metal or amine addition salt forms which the compounds of formula (I) are able to form. Said salts can conveniently be obtained by treating the compounds of formula (I) containing acidic hydrogen atoms with appropriate organic and inorganic bases such as, for example, the ammonium salts, the alkali and earth alkaline metal salts, e.g. the lithium, sodium, potassium, magnesium, calcium salts and the like, salts with organic bases, e.g. the benzathine, N-methyl-D-glucamine, hydrabamine salts, and salts with amino acids such as, for example, arginine, lysine and the like.
Conversely said salt forms can be converted by treatment with an appropriate base or acid into the free acid or base form. The term addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) are able to form and said solvates are meant to be included within the scope of the present invention. Examples of such solvates are, e.g. the hydrates, alcoholates and the like. The compounds of formula (I) wherein R is other than hydrogen have an asymmetric carbon atom in their structure, the absolute configuration of which may be represented by the descriptors R and S. Formula (I) is intended to encompass all enantiomers and diastereoisomers of the compounds of the invention as well as the mixtures thereof, in particular the racemates and the enantiomerically pure forms (i.e. the enantiomeric excess is equal to or higher than 95%).
Further, the compounds of formula (I) may contain in their structure a tautomeric system and, consequently, these compounds can be represented by each of their tautomeric forms. All tautomeric forms are meant to be embraced by the definition of the compounds of formula (I).
In particular, the present invention is concerned with the use of a compound of formula (I) wherein R is phenyl or substituted phenyl; R1 is hydrogen or C1-6alkyl; R2 is hydrogen; halo; C1-6alkyl; C1-4alkyl substituted with up to 4 halo atoms;
C3-7cycloalkyl; phenyl; substituted phenyl; C1-6alkyl substituted with phenyl or substituted phenyl; said substituted phenyl representing phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, trifluoromethyl,
C1-6alkyl, C1-6alkyloxy and cyano. Interesting compounds within the invention are the compounds of formula (I) wherein the 1H-imidazol-1-ylmethyl moiety is substituted on either the 4, 5, 6 or 7 position of the benzimidazole ring.
More interesting compounds are the compounds of formula (I) wherein the 1H-imidazol-1-ylmethyl moiety is substituted on either the 5 or 6 position of the benzimidazole ring.
Another group of interesting compounds within the present invention are those compounds wherein R1 is hydrogen; and R2 is hydrogen, C1-6alkyl or phenyl. The preferred compounds within the invention are (±)-5-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-benzimidazole (generically known as liarozole), (+)-liarozole, (-) liarozole and the pharmaceutically acceptable addition salts thereof, in particular, the hydrochloride and the fumarate salts such as, for example, liarozole hydrochloride, liarozole fumarate, (+)-liarozole hydrochloride and (-)-liarozole hydrochloride.
The preparation of the compounds of formula (I) is described in EP-0,260,744,
EP-0,371,559, WO 95/22540 and WO 95/22541. Vitamin D3 is sequentially metabolized by enzymes, first to 25-hydroxy-vitamin D3 in the liver and then to either 24,25-dihydroxy-vitamin D3 or the active hormonal form 1α,25-dihydroxy-vitamin D3 in the kidney. Vitamin D3 (generically known as cholecalciferol) and 25-hydroxy-vitamin D3 (generically known as calcifediol), therefore, are prodrugs of the subject active compound calcitriol. Another prodrug of calcitriol is 1α-hydroxy-vitamin D3 (generically known as alfacalcidol), which is hydroxylated at the 25 position in the liver to give calcitriol. Calcitriol is further metabolized to inactive degradation products, e.g. in the kidney and the skin. The compounds of formula (I) are useful in inhibiting the metabolic degradation of endogenously formed and exogenously administered calcitriol. The inhibitory activity of the compounds of formula (I) on the metabolic degradation of calcitriol is evidenced by measuring the impact of said compounds on the calcitriol degradation in human foreskin keratinocytes, pig kidney cells and human hepatoma cells, as described hereinafter. In view of the useful inhibitory activity of the compounds of formula (I) on the metabolic degradation of calcitriol, the therapeutic potential of the compounds of formula (I), optionally in combination with calcitriol or a prodrug thereof, preferably, cholecalciferol, calcifediol or alfacalcidol, extends to all pathological conditions which are beneficially influenced by inhibiting the metabolic degradation of calcitriol. For instance, the compounds of formula (I) optionally in combination with calcitriol or a prodrug thereof, preferably, cholecalciferol, calcifediol or alfacalcidol, can be useful in the treatment of vitamin D deficiency states. Vitamin D deficiency may arise from inadequate exposure to sunlight and/or from a lack of the vitamin in the diet and is further aggravated by the rapid metabolic degradation of calcitriol, and leads to a syndrome characterized by hypocalcaemia, hypophosphataemia, bone softening and bone pain. Other clinical applications of the compounds of formula (I) optionally in combination with calcitriol or a prodrug thereof, preferably, cholecalciferol, calcifediol or alfacalcidol, are reviewed by Bouillon et al., Endocrine Reviews (1995) 16(2), 200-257 and include metabolic bone disorders, e.g. osteoporosis, osteopetrosis and the like; primary and secundary hyperparathyroidism; renal osteodystrophy; diseases of the immune system or other conditions characterized by an abnormal interleukin production, e.g. inflammatory diseases such as rheumatoid arthritis and asthma; hypertension; diabetes mellitus;
diseases characterized by abnormal cell proliferation and/or differentiation, such as cancer, e.g. leukemia, carcinoma, sarcoma, lymphoma and the like; and, in particular, keratinization disorders, e.g. acne, psoriasis, lamellar ichthyosis, plantar warts, callosities, acanthosis nigricans, lichen planus, molluscum, melasma, corneal epithelial abrasion, geographic tongue, Fox-Fordyce disease, cutaneous metastatic melanoma and keloids, epidermolytic hyperkeratosis, Darier's disease, pityriasis rubra pilaris, congenital ichthyosiform erythroderma, hyperkeratosis palmaris et plantaris, and similar disorders. The usefulness in the treatment and/or prevention of keratinization disorders may be demonstrated in the "Vaginal Keratinazation Test in Ovariectomized Rats" (J. Pharmacol. Exper. Therap.(1992) 261(2), 773-779).
Thus, the present invention concerns the use of (1H-imidazol-1-yl)methyl-1H-benzimidazoles of formula (I) for the manufacture of a medicament for treating a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol. Also, the present invention concerns a method of treating patients suffering from a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol, said method consisting of administering to a patient an effective amount of a compound of formula (I), an addition salt or a stereochemically isomeric form thereof.
Another aspect of the incvention concerns the use of (1H-imidazol-1-yl)methyl-1H-benzimidazoles of formula (I) in combination with calcitriol or a prodrug thereof for the manufacture of a medicament for treating a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol. Also, this aspect of the invention concerns a method of treating patients suffering from a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol, in particular keratinization disorders such as psoriasis, said method consisting of administering to a patient (a) an effective amount of calcitriol or a prodrug thereof and (b) an effective amount of a compound of formula (I), an addition salt or a stereochemically isomeric form thereof.
As mentioned hereinabove, the invention relates to a single drug therapy involving a compound of formula (I), as well as a combination therapy including a compound of formula (I) and calcitriol or a prodrug thereof. For both types of therapy, the active ingredients each independently may be administered orally, rectally, percutaneously, topically or by parenteral injection, depending on the affliction to be treated and the evaluation of the physician prescribing the treatment with the subject drugs.
Preferably, the drugs each independently are administered orally or topically. In case of a combination therapy, the compounds of formula (I) and calcitriol or a prodrug thereof may be administered separately (i.e. simultaneously, concurrently or consecutively) or the different drugs may be combined in one dosage form. A particular embodiment of the invention relates to a product containing (a) a
pharmaceutical composition containing an effective amount of calcitriol or a prodrug thereof and (b) a pharmaceutical composition containing an effective amount of a compound of formula (I), an addition salt or a stereochemically isomeric form thereof, as a combined preparation for simultaneous, separate or sequential use in pathological conditions which are beneficially influenced by inhibiting the metabolic degradation of calcitriol, in particular, keratinization disorders such as psoriasis. Preferentially, the product contains (a) a pharmaceutical composition containing an effective amount of calcitriol or a prodrug thereof and (b) a pharmaceutical composition containing an effective amount of (±)-5-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-benzimidazole (generically known as liarozole), (+)-liarozole, (-) liarozole or a pharmaceutically acceptable addition salt thereof, in particular, liarozole hydrochloride, liarozole fumarate, (-f-)-liarozole hydrochloride and (-)-liarozole hydrochloride. Such products may comprise, for example, a kit comprising a container with a suitable composition containing calcitriol or a prodrug thereof and another container comprising a compound of formula (I), an addition salt or a stereochemically isomeric form thereof.
Such a product may have the advantage that a physician can select on the basis of the diagnosis the appropriate amounts of each component and the sequence and timing of the administration thereof.
Whether or not the compounds of formula (I) and calcitriol are administered separately or together, the drugs are preferably formulated in specific compositions thereof. As appropriate compositions there may be cited all compositions usually employed for systemically or topically administering drugs. To prepare the pharmaceutical
compositions of this invention, an effective amount of the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed such as, for example, water, glycols, oils, alcohols and the like in the case of oral hquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules, and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. As appropriate compositions for topical application there may be cited all compositions usually employed for topically administering drugs, e.g. creams, gels, dressings, shampoos, tinctures, pastes, ointments, salves, powders and the like.
Application of said compositions may be by aerosol, e.g. with a propellent such as nitrogen carbon dioxide, a freon, or without a propellent such as a pump spray, drops, lotions, or a semisolid such as a thickened composition which can be applied by a swab.
In order to enhance the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions, it can be advantageous to employ α-, β- or γ-cyclodextrins or their derivatives, in particular hydroxyalkyl substituted cyclodextrins, e.g.
2-hydroxypropyl-b-cyclodextrin. Acid or base addition salts of compounds of formula (I) due to their increased water solubility over the corresponding base or acid form, are obviously more suitable in the preparation of aqueous compositions. Also co-solvents such as alcohols may improve the solubility and/or the stability of the compounds of formula (I) in pharmaceutical compositions.
For systemic administration, it is advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets
(including scored or coated tablets), capsules, pills, powders packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
Other such compositions are preparations of the cosmetic type, such as toilet waters, lotions, skin milks or milky lotions. Said preparations contain, besides the active ingredients, components usually employed in such preparations. Examples of such components are oils, fats, waxes, surfactants, humectants, thickening agents, antioxidants, viscosity stabilizers, chelating agents, buffers, preservatives, perfumes, dvestuffs, lower alkanols, and the like. Apart from the above-described compositions, covers may be used, e.g. plasters, bandages, dressings, gauze pads and the like, containing an appropriate amount of a composition as referred hereinabove. In particular, covers may be applied which have been impregnated or sprinkled with a liquid formulation containing the active agents, or strewn with a powdery solid composition, or smeared, covered or coated with a semiliquid composition.
Hence, particular compositions are those adapted for topical administration. The latter compositions comprise a skin-acceptable carrier, an effective amount of a compound of formula (I), an addition salt or a stereochemically isomeric form thereof, and an effective amount of calcitriol or a prodrug thereof.
In general it is contemplated that an effective daily dose of a compound of formula (I), an addition salt or a stereochemically isomeric form thereof would be from 0.001 mg/kg to 20 mg/kg body weight and more preferably from 0.01 mg/kg to 10 mg/kg body weight. The effective daily dose of calcitriol or a prodrug thereof ranges from about 0.1 μg to about 10 mg, in particular from about 0.5 μg to about 1 mg and preferably from about 1 μg to about 0.1 mg. It may be appropriate to administer the required dose as several sub-doses at appropriate intervals throughout the day. In particular, (+)-liarozole hydrochloride, (-)-liarozole hydrochloride or (±)-liarozole hydrochloride is suitably administered b.i.d..
Preferred compositions for topical application comprise from 0.005 to 0.5% w/w (particularly from 0.01 to 0.1%) calcitriol and/or from 0.05 to 5% of (+)-liarozole hydrochloride, (-)-liarozole hydrochloride or (±)-liarozole hydrochloride, in a semi-solid or liquid diluent or carrier. The topical compositions are applied to the area to be treated or protected at regular intervals as needed, generally about 7 to about 21 times per week. The duration of the treatment will depend upon the nature and severity of the condition to be treated as well as the frequency of application of the composition.
The following examples are intended to illustrate and not to limit the scope of the present invention in all its aspects.
Experimental part
A) Composition Examples
The following formulations exemplify typical pharmaceutical compositions in dosage unit form suitable for administration to warm-blooded animals in accordance with the present invention. "Active ingredient 1" (A.I. 1) as used throughout these examples relates to a compound of formula (I), a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof. "Active ingredient 2" (A.I. 2) relates to calcitriol or a prodrug thereof. Formulations containing a single active ingredient as well as those comprising both active ingredients are exemplified.
Example 1 : ORAL SOLUTION
9 g of methyl 4-hydroxybenzoate and 1 g of propyl 4-hydroxy-benzoate were dissolved in 4 1 of boiling purified water. In 3 1 of this solution were dissolved first 10 g of 2,3-dihydroxybutanedioic acid and thereafter 20 g of A.I. 1 and/or 0.2 g of A.I. 2. The latter solution was combined with the remaining part of the former solution and 12 1 1,2,3-propane-triol and 3 1 of sorbitol 70% solution were added thereto. 40 g of sodium saccharin were dissolved in 0.5 1 of water and 2 ml of raspberry and 2 ml of gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 201 providing an oral solution comprising 5 mg of A.I. 1 and/or 0.05 mg of A.I. 2 per teaspoonful (5 ml). The resulting solution was filled in suitable containers.
Example 2: CAPSULES
20 g of A.I. 1 and/or 0.2 g of A.I. 2, 6 g sodium lauryl sulfate, 56 g starch, 56 g lactose, 0.8 g colloidal silicon dioxide, and 1.2 g magnesium stearate were vigorously stirred together. The resulting mixture was subsequently filled into 1000 suitable hardened gelatin capsules, each comprising 20 mg of A.I. 1 and/or 0.2 mg of A.I. 2. Example 3 : INJECTABLE SOLUTION
0.5 mg A.I. 1 and/or 0.05 mg A.I. 2, 50 mg glucose anhydrous and 0.332 ml concentrated hydrochloric acid were mixed with 0.8 ml water for injections. Sodium hydroxide was added until pH = 3.2 ± 0.1 and water was added to 1 ml. The solution was sterilized and filled in sterile containers.
Example 4 : 2% CREAM
75 mg stearyl alcohol, 2 mg cetyl alcohol, 20 mg sorbitan monostearate and 10 mg isopropyl myristate are introduced into a doublewall jacketed vessel and heated until the mixture has completely molten. This mixture is added to a separately prepared mixture of purified water, 200 mg propylene glycol and 15 mg polysorbate 60 having a temperature of 70 to 75°C while using a homogenizer for liquids. The resulting emulsion is allowed to cool to below 25°C while continuously mixing. A solution of 20 mg A.I. 1 and/or 0.2 mg A.I. 2, 1 mg polysorbate 80 and purified water and a solution of 2 mg sodium sulfite anhydrous in purified water are next added to the emulsion while continuously mixing. The cream, 1 g of the A.I. 1 and/or 10 mg A.I. 2 are homogenized and filled into suitable tubes.
Example 5 : 2% TOPICAL GEL
To a solution of 200 mg hydroxypropyl β-cyclodextrine in purified water is added 20 mg A.I. 1 and/od 0.2 mg A.I. 2 while stirring. Hydrochloric acid is added until complete dissolution and then sodium hydroxide is added until pH 6.0. This solution is added to a dispersion of 10 mg carrageenan PJ in 50 mg propylene glycol while mixing. While mixing slowly, the mixture is heated to 50°C and allowed to cool to about 35°C whereupon 50 mg ethyl alcohol 95% (v/v) is added. The rest of the purified water q.s. ad 1 g is added and the mixture is mixed to homogenous.
Example 6 : 2% LIPOSOME FORMULATION
A mixture of 2 g A.I. 1 and/or 0.02 g A.I. 2 microfine, 20 g phosphatidyl choline, 5 g cholesterol and 10 g ethyl alcohol is stirred and heated at 55-60°C until complete dissolution and is added to a solution of 0.2 g methyl paraben, 0.02 g propyl paraben,
0.15 g disodium edetate and 0.3 g sodium chloride in purified water while
homogenizing. 0.15 g Hydroxypropylmethylcellulose in purified water ad 100 g is added and the mixing is continued until swelling is complete.
Example 7 : 2% LIPOSOME FORMULATION
A mixture of 10 g phosphatidyl choline and 1 g cholesterol in 7.5 g ethyl alcohol is stirred and heated at 40°C until complete dissolution. 2 g A.I. 1 and/or 0.02 g A.I. 2 microfine is dissolved in purified water by mixing while heating at 40°C. The alcoholic solution is added slowly to the aqueous solution while homogenizing during 10 minutes.
1.5 g Hydroxypropylmethylcellulose in purified water is added while mixing until swelling is complete. The resulting solution is adjusted to pH 5.0 with sodium hydroxide
1 N and diluted with the rest of the purified water ad 100 g. Example 8 : TOPICAL CREAM
2% topical cream
To a solution of 200 mg hydroxypropyl β-cyclodextrine in purified water is added 20 mg of A.I. 1 and/or 0.2 mg A.I. 2 while stirring. Hydrochloric acid is added until complete dissolution and next sodium hydroxide is added until pH 6.0. While stirring, 50 mg glycerol and 35 mg polysorbate 60 are added and the mixture is heated to 70°C. The resulting mixture is added to a mixture of 100 mg mineral oil, 20 mg stearyl alcohol, 20 mg cetyl alcohol, 20 mg glycerol monostearate and 15 mg sorbate 60 having a temperature of 70°C while mixing slowly. After cooling down to below 25°C, the rest of the purified water q.s. ad 1 g is added and the mixture is mixed to homogenous.
In a similar way a 1%, a 3% and a 5% topical cream containing the following ingredients were prepared :
Figure imgf000014_0001
Example 9 : SUPPOSITORIES
3 g A.I. 1 and/or 0.03 g A.I. 2 was dissolved in a solution of 3 g 2,3-dihydroxybutanedioic acid in 25 ml polyethylene glycol 400. 12 G surfactant and triglycerides q.s. ad 300 g were molten together. The latter mixture was mixed well with the former solution. The thus obtained mixture was poured into moulds at a temperature of 37~38°C to form 100 suppositories each containing 30 mg of the active ingredient. B) Biological Example
Example 10 : Metabolism of calcitriol by human foreskin keratinocytes, pig kidney cells and human hepatoma cells The dermal and epidermal tissues of human foreskin was cut in 0.5 cm^ pieces and incubated overnight at 4°C in 10 ml phosphate buffer (PBS) without calcium and magnesium, containing 2 ml Dispase II (a protease supplied by Boehringer Mannheim at an activity of 24U/ml). After incubation, the tissue was placed in 15 ml trypsin
(0.125%) - EDTA (0.01%) and the epidermal fraction was carefully lifted with a pincet. By gently scraping the dermis, the adherent keratinocytes were released from the tissue into the trypsin solution. After removal of all dermal parts, the remaining solution (containing the keratinocytes and the stratum corneum sheets) was incubated for 20 min. at 37°C. After filtration, the filter was washed once with keratinocyte-free medium (SFM) and fetal calf serum was added to the filtrate to reach a final concentration of 10% (inactivation of the trypsin-EDTA). After centrifugation of the cell suspension (10 min. at 1000 rpm), the cells were counted and plated in keratinocyte-SFM (supplemented with an antibiotic-antimycotic mix and 2 μg gentamycin/ml) at a cell density of 3.106 cells/75 cm2 tissue culture flask and incubated at 37°C in a 5%-CO2 humidified atmosphere. After 2-3 days of cultivation, the medium was replaced by antibiotic-antimycotic-free medium. After reaching confluence, cells were trypsinized and, after inactivation of the remaining trypsine by fetal calf serum, seeded in 6-well-plates at a cell density of 1.105 cells/ml keratinocyte-SFM. The medium was refreshed every 2-3 days and 16 hours before the onset of the experiment. At the start of the experiment, the medium was again replaced by 2 ml of keratinocyte-SFM. The calcitriol metabolism was initiated by adding 0.1 μCi 1α,25-[26,27-3H]-dihydroxyvitamin-D3 in 10 μl ethanol and 2 μl drug and/or solvent (DMSO). At the end of a three hour incubation period, the medium was transferred into a brown coloured test tube containing 3 ml chloroform and 0.5 ml 10% formic acid. The cells were trypsinized with 0.5 ml trypsine (0.125%) - EDTA (0.01%) and after 15 min. incubation at room temperature combined with the medium -chloroform mixture. The 6- well plates were washed twice with 1.5 ml methanol which was added to the extraction tube. After 20 min. of extraction, the chloroform layer was separated from the water layer by centrifugation (10 min. at 2400 rpm) and the water layer reextracted with 3 ml chloroform. After evaporation of the chlorofrom under a stream of nitrogen, calcitriol and its metabolites were dissolved in 0.2 ml n-hexane:isopropanol (90:10) and analyzed by HPLC.
Pig kidney cells collected from one 75 cm2 tissue culture flask were suspended in 160 ml Medium 199 (a synthetic culture medium supplied by Life-Technologies) containing 3% foetal calf serum (FCS). Two ml of the cell suspension were seeded in 6-well plates and incubated at 37°C in a humidified 5% CO2 atmosphere. The medium was refreshed every 2-3 days. At the onset of the experiment, confluent cultures were washed with phosphate buffer (PBS) without calcium and magnesium and refreshed with with 2 ml medium 199 without serum. The metabolism of lα,25-[26,27-3H]-dihydroxyvitamin- D3 was studied as described for the human foreskin keratinocytes.
Human hepatoma cells were grown at 37°C (in a CO2 incubator) in 2 ml REG A-3 medium (a synthetic culture medium supplied by Life-Technologies) supplemented with 5% FCS. After 24 h of growth, 1.25 μCi [14C]-acetate, drug and/or DMSO were added and cells were grown for another 24 h. At the end of the incubation period, cells were collected by centrifugation, washed with physiological saline and resuspended in 1 ml H2O and 1 ml 15% KOH in 90% ethanol. The metabolism of 1α,25-[26,27-3H]- dihydroxyvitamin-D3 was studied as described for the human foreskin keratinocytes.
After effecting the above test procedures, IC50 values for the compounds of formula (I) were calculated by conventional techniques. Table 1 summarizes the obtained IC50 values for some of the subject compounds.
Figure imgf000016_0001

Claims

Claims
1. The use of a (1H-imidazol-1-yl)methyl-1H-benzimidazole for the manufacture of a medicament for treating a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol, said benzimidazole having the formula
Figure imgf000017_0001
wherein
R is hydrogen; C1- 10alkyl; C3-7cycloalkyl; Ar1 or Ar1-C1-6alkyl;
R1 is hydrogen; C3-7cycloalkyl; Ar1; C1- 10alkyl; C1-6alkyl substituted with Ar1 or C3-7cycloalkyl; hydroxy; C1- 10alkyloxy; C loalkyloxy substituted with Ar1 or C3-7cycloalkyl; C3-6alkenyloxy optionally substituted with Ar2; C3-6alkynyloxy optionally substituted with Ar2; or Ar1-oxy;
R2 is hydrogen; halo; C1-10alkyl; C1 -4alkyl substituted with up to 4 halo atoms;
C3-7Cycloalkyl; Ar1; quinolinyl; indolinyl; C1-6alkyl substituted with Arl,
C3-7cycloalkyl, quinolinyl, indolinyl or hydroxy; C1- 10alkyloxy; C1 -6alkyloxy substituted with Ar1 or C3-7cycloalkyl; C3-6alkenyl optionally substituted with Ar1;
Ar2-oxy; C1-6alkyloxycarbonyl; carboxyl; C1-6alkylcarbonyl; Ar1-carbonyl or Ar1-(CΗOΗ)-;
each Ar1 independently is phenyl, substituted phenyl, pyridinyl, aminopyridinyl, imidazolyl, thienyl, halothienyl, furanyl, halofuranyl or thiazolyl;
each Ar2 independently is phenyl or substituted phenyl;
in Ar1 and Ar2 said substituted phenyl represents phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, trifluoromethyl,
C1-6alkyl, C1 -6alkyloxy, cyano, amino, mono- and di(C1 -6alkyl)amino, nitro, carboxyl, formyl and C1-6alkyloxycarbonyl,
a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof. 2. The use of a (1H-imidazol-1-yl)methyl-1H-benzimidazole as claimed in claim 1 wherein
R is phenyl or substituted phenyl;
R1 is hydrogen or C loalkyl; R2 is hydrogen; halo; C1-6alkyl; C1-4alkyl substituted with up to 4 halo atoms;
C3-7cycloalkyl; phenyl; substituted phenyl; C1-6alkyl substituted with phenyl or substituted phenyl;
said substituted phenyl represents phenyl substituted with 1,
2 or 3 substituents each independently selected from halo, hydroxy, trifluoromethyl, C1-6alkyl, C1-6alkyloxy and cyano.
3. The use of a (1H-imidazol-1-yl)methyl-1H-benzimidazole as claimed in claim 1 wherein the compound of formula (I) is a 5-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-benzimidazole.
4. The use of a (1H-imidazol-1-yl)methyl-1H-benzimidazole as claimed in claim 1 wherein the compound of formula (I) is used in combination with calcitriol or a prodrug thereof.
5. The use of a (1H-imidazol-1-yl)methyl-1H-benzimidazole as claimed in claim 4 wherein the pathological condition is a keratinization disorder.
6. The use of a (1H-imidazol-1-yl)methyl-1H-benzimidazole as claimed in claim 5 wherein the pathological condition is psoriasis.
7. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and as active ingredients (a) an effective amount of calcitriol or a prodrug thereof, and (b) an effective amount of a compound of formula (I) as described in any one of claims 1 to 3.
8. A pharmaceutical composition as claimed in claim 7 wherein the active ingredients are (a) calcitriol, and (b) a 5-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-benzimidazole.
9. A pharmaceutical composition as claimed in claim 7 or 8 wherein the composition is adapted for topical administration.
10. A pharmaceutical composition as claimed in claim 9 wherein the composition comprises from 0.005 to 0.5% w/w calcitriol and from 0.05 to 5% of a
5-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-benzimidazole, in a semi-solid or liquid diluent or carrier.
11. A pharmaceutical composition as claimed in claim 10 wherein the composition comprises from 0.01 to 0.1% w/w calcitriol.
12. A process for preparing a composition as claimed in any of claims 7 to 11, characterized in that an effective amount of calcitriol or a prodrug thereof and an effective amount of a compound of formula (I) as described in any one of claims 1 to 3 are combined in intimate admixture with the pharmaceutically acceptable carrier.
13. A product containing (a) a pharmaceutical composition containing an effective amount of calcitriol or a prodrug thereof and a pharmaceutical acceptable carrier, and (b) a pharmaceutical composition containing an effective amount of a compound of formula (I) as described in any one of claims 1 to 3, and a pharmaceutical acceptable cairier, as a combined preparation for simultaneous, separate or sequential use in the treatment of pathological conditions which are beneficially influenced by inhibiting the metabolic degradation of calcitriol.
14. A product according to claim 13 wherein the product contains (a) a pharmaceutical composition containing calcitriol, and (b) a pharmaceutical composition containing a
5-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-benzimidazole.
15. A product according to claim 14 wherein the product is adapted for topical administration.
16. A product according to claim 15 wherein the product contains (a) a pharmaceutical composition containing from 0.005 to 0.5% w/w calcitriol, and (b) a pharmaceutical composition containing from 0.05 to 5% of a 5-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-benzimidazole.
17. A product according to claim 16 wherein the product contains a pharmaceutical composition containing from 0.01 to 0.1% w/w calcitriol.
18. A product according to any one of claims 13 or 17 as a combined preparation for simultaneous, separate or sequential use in the treatment of keratinization disorders.
19. A product according to any one of claims 13 or 17 as a combined preparation for simultaneous, separate or sequential use in the treatment of psoriasis.
20. A method of treating patients suffering from a pathological condition which is beneficially influenced by inhibiting the metabolic degradation of calcitriol, comprising the administration to said patients of an effective amount of a (1H-imidazol-1-yl)methyl-1H-benzimidazole, said benzimidazole having the formula
Figure imgf000020_0001
wherein
R is hydrogen; C1- 10alkyl; C3-7cycloalkyl; Ar1 or Ar1-C1 -6alkyl;
R1 is hydrogen; C3-7cycloal kyl; Ar1; C1-10alkyl; C1-6alkyl substituted with Ar1 or C3-7cycloalkyl; hydroxy; C1-10alkyloxy; C1-6alkyloxy substituted with Ar1 or C3-7cycloalkyl; C3-6alkenyloxy optionally substituted with Ar2; C3-6alkynyloxy optionally substituted with Ar2; or Ar1-oxy;
R2 is hydrogen; halo; C1- 10alkyl; C1 -4alkyl substituted with up to 4 halo atoms; C3-7cycloalkyl; Ar1; quinolinyl; indolinyl; C1-6alkyl substituted with Ar1,
C3-7cycloalkyl, quinolinyl, indoUnyl or hydroxy; C1 - 10alkyloxy; C1-6alkyloxy substituted with Ar1 or C3-7cycloalkyl; C3-5alkenyl optionally substituted with Ar1;
Ar2-oxy; C1-6alkyloxycarbonyl; carboxyl; C1-5alkylcarbonyl; Ar1-carbonyl or
Ar1-(CHOH)-;
each Ar1 independently is phenyl, substituted phenyl, pyridinyl, aminopyridinyl, imidazolyl, thienyl, halothienyl, furanyl, halofuranyl or thiazolyl;
each Ar2 independently is phenyl or substituted phenyl;
in Ar1 and Ar2 said substituted phenyl represents phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, trifluoromethyl, C1-6alkyl, C1-6alkyloxy, cyano, amino, mono- and di(C1-6alkyl)amino, nitro, carboxyl, formyl and C1-6alkyloxycarbonyl,
a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.
21. A method according to claim 20 wherein
R is phenyl or substituted phenyl;
R1 is hydrogen or C1-6alkyl;
R2 is hydrogen; halo; C1-6alkyl; C1-4alkyl substituted with up to 4 halo atoms;
C3-7cycloalkyl; phenyl; substituted phenyl; C1-6alkyl substituted with phenyl or substituted phenyl;
said substituted phenyl represents phenyl substituted with 1, 2 or 3 substituents each independently selected from halo, hydroxy, trifluoromethyl, C1-6alkyl, C1-6alkyloxy and cyano.
22. A method according to claim 21 wherein the compound of formula (I) is a
5-[(3-chlorophenyl)(1H-imidazol-1-yl)methyl]-1H-benzimidazole.
23. A method according to claim 20 wherein the compound of formula (I) is
administered in combination with an effective amount of calcitriol or a prodrug thereof.
24. A method according to claim 23 wherein the pathological condition is a keratinization disorder.
25. A method according to claim 24 wherein the pathological condition is psoriasis.
PCT/EP1995/005172 1994-12-28 1995-12-21 Benzimidazoles as inhibitors of calcitriol metabolism WO1996019991A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU44361/96A AU4436196A (en) 1994-12-28 1995-12-21 Benzimidazoles as inhibitors of calcitriol metabolism
EP95943236A EP0800391A1 (en) 1994-12-28 1995-12-21 Benzimidazoles as inhibitors of calcitriol metabolism
JP8520221A JPH10511653A (en) 1994-12-28 1995-12-21 Benzimidazoles as inhibitors of calcitriol metabolism

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP94203774.8 1994-12-28
EP94203774 1994-12-28

Publications (1)

Publication Number Publication Date
WO1996019991A1 true WO1996019991A1 (en) 1996-07-04

Family

ID=8217502

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/005172 WO1996019991A1 (en) 1994-12-28 1995-12-21 Benzimidazoles as inhibitors of calcitriol metabolism

Country Status (4)

Country Link
EP (1) EP0800391A1 (en)
JP (1) JPH10511653A (en)
AU (1) AU4436196A (en)
WO (1) WO1996019991A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044414A2 (en) 1998-03-03 1999-09-10 Kristoffer Larsen Innovation A/S Animal breeding system
US8188131B2 (en) 2008-02-07 2012-05-29 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh1 expression
US8501770B2 (en) 2009-12-30 2013-08-06 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
US8609688B2 (en) 2011-06-24 2013-12-17 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0371559A2 (en) * 1988-11-29 1990-06-06 Janssen Pharmaceutica N.V. Use of benzimidazoles in the treatment of epithelial disorders
WO1995022540A1 (en) * 1994-02-18 1995-08-24 Janssen Pharmaceutica N.V. Enantiomerically pure (+)-liarozole

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0371559A2 (en) * 1988-11-29 1990-06-06 Janssen Pharmaceutica N.V. Use of benzimidazoles in the treatment of epithelial disorders
WO1995022540A1 (en) * 1994-02-18 1995-08-24 Janssen Pharmaceutica N.V. Enantiomerically pure (+)-liarozole

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
G. DANEELS ET AL.: "Modulation of Ca2+-induced normal human keratinocyte differentation by liarozole HCl.", CELL BIOLOGY INTERNATIONAL, vol. 18, no. 5, pages 558, XP000568167 *
G.G. KRUEGER ET AL.: "Psoriasis therapy - observational or rational?", NEW ENGL. J. MED., vol. 328, no. 25, pages 1845 - 1846, XP000568134 *
J. ZHAO ET AL.: "Potentialization of vitamin D (analogs) by cytochrome P-450 enzyme inhibitors is analog- and cell-type specific.", PROC. WORKSHOP VITAM. D, vol. 9, pages 186 - 187, XP000568192 *
P. DOCKX ET AL.: "Inhibition of the metabolism of endogenous retinoic acid as treatment for severe psoriasis: an open study with oral liarozole", BR. J. DERMATOL., vol. 133, no. 3, pages 426 - 432, XP000568170 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999044414A2 (en) 1998-03-03 1999-09-10 Kristoffer Larsen Innovation A/S Animal breeding system
US8188131B2 (en) 2008-02-07 2012-05-29 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh1 expression
US8859597B2 (en) 2008-02-07 2014-10-14 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh1 expression
US9433610B2 (en) 2008-02-07 2016-09-06 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh1 expression
US10406163B2 (en) 2008-02-07 2019-09-10 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh1 expression
US11160808B2 (en) 2008-02-07 2021-11-02 Massachusetts Eye & Ear Infirmary Compounds that enhance Atoh1 expression
US8501770B2 (en) 2009-12-30 2013-08-06 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
US8609688B2 (en) 2011-06-24 2013-12-17 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
US8815854B2 (en) 2011-06-24 2014-08-26 Arqule, Inc. Substituted imidazopyridinyl compounds
US8962619B2 (en) 2011-06-24 2015-02-24 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds

Also Published As

Publication number Publication date
JPH10511653A (en) 1998-11-10
EP0800391A1 (en) 1997-10-15
AU4436196A (en) 1996-07-19

Similar Documents

Publication Publication Date Title
JP2912596B2 (en) Benzimidazole derivatives
JP3006888B2 (en) Drugs based on metronidazole or a synergistic mixture of metronidazole and clindamycin
EP0630228B1 (en) Agent for regulating the greasiness of the skin
EP1439837B1 (en) Pyrazolidinone compounds as ligands of the prostaglandin ep2 and/or ep4 receptors
JP6045495B2 (en) Ester prodrug of [3- (1- (1H-imidazol-4-yl) ethyl) -2-methylphenyl] methanol for reducing intraocular pressure
HUT71481A (en) Pharmaceutical compositions for treatment of seborrea and acne containing 2-phenyl-3-aroyl-benzothiophene derivatives and process for their preparation
US5849279A (en) Agent for regulating the greasiness of the skin
EP0800391A1 (en) Benzimidazoles as inhibitors of calcitriol metabolism
CA2016985C (en) Dehydrocholecalciferol derivatives
US6730703B2 (en) Dual inhibitors of cholesteryl ester and wax ester synthesis for sebaceous gland disorders
EP0800524B1 (en) 6-[triazolyl[ 3-(trifluoromethyl)phenyl]methyl]-2-quinolinones and -quinolinethiones
KR20040021724A (en) Cosmetic Composition Comprising Novel Pseudo Ceramide for Preventing and Alleviating Atopic Dermatitis
US5369126A (en) Nonatetraenoic acid derivative for use in treating acne
US6022532A (en) Agent for regulating the greasiness of the skin
JPH09508914A (en) Enantiomerically Pure (+)-Lialozole
WO1993020817A1 (en) Novel use of nitroimidazoles
JPH1017474A (en) Psoriasis treatment
HK1006208B (en) Agent for regulating the greasiness of the skin
MXPA97004667A (en) 6- [triazolil [3-trifluoromethyl) phenyl] methyl] -2-quinolinones and quinolinotium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KP KR KZ LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995943236

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 836194

Date of ref document: 19970512

Kind code of ref document: A

Format of ref document f/p: F

WWP Wipo information: published in national office

Ref document number: 1995943236

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995943236

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA